High-dose radiation with Keytruda led to increased infiltration of various immune cells and formation of tertiary lymphoid ...

Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.

Immutep Limited (NASDAQ:IMMP) is a biotechnology company developing therapies for cancer and autoimmune diseases. The firm’s ...

In a boost for its phase III Indonesian diabetic foot infection trial, Recce becomes eligible for up to $85 million of ...

Zydus Lifesciences Limited (including its subsidiaries and affiliates), an innovation-led life-sciences company, with an ...

Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a ...

SAN ANTONIO -- Preoperative radiotherapy (RT) plus PD-1 inhibitor pembrolizumab (Keytruda) significantly increased immune ...

Formycon AG will be responsible for the development, registration, manufacture and supply of the product. Zydus Lifesciences ...

Ahmedabad: Zydus Lifesciences Limited, a life-sciences company, with an international presence, has announced that its wholly ...

Formycon will develop, register, manufacture, and supply the product, while Zydus will be responsible for commercialization.

One catalyst happened a couple of weeks ago, when Merck's stock popped by nearly 4% on encouraging clinical data. Let's look ...

Under the terms of this agreement, Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the ...